title: Pharmacokinetics of tocolytic agents.
abstract: Tocolytic agents are drugs designed to inhibit contractions of myometrial smooth muscle cells. Such an effect has been demonstrated in vitro or in vivo for several pharmacological agents, including beta-adrenergic agonists, calcium channel antagonists, oxytocin antagonists, NSAIDs and magnesium sulfate. However, the aim of tocolysis is not only to stop uterine contractions or to prevent preterm delivery, but to prevent perinatal morbidity and mortality associated with preterm birth. The achievement of this goal has not yet been clearly demonstrated for any of the drugs available, and the use of tocolytic agents may appear controversial. Therefore, it is important to avoid maternal and fetal toxicity when tocolytic agents are used. During pregnancy, all steps of drug pharmacokinetics are altered. Absorption of drugs administered orally is limited because of delayed stomach emptying and reduced intestinal motility. The volume of distribution of drugs is increased. The metabolic activity of the liver is increased, accelerating the metabolism of lipophilic drugs. Renal filtration is increased, leading to enhanced renal elimination of water-soluble drugs. These modifications are generally responsible for reduced plasma concentration and reduced half-life of most drugs. These specific modifications have to be taken into account when using a drug in pregnant women. The aim of this review is to provide the reader with pharmacological data about drugs currently used to treat preterm labour. Such data in pregnant women may affect the choice of optimal drug dosage and route of administration.
authors.affiliation: Maternité Port-Royal, Université René Descartes, Paris, France.
authors.forename: Vassilis
authors.initials: V
authors.lastname: Tsatsaris
authors.forename: Dominique
authors.initials: D
authors.lastname: Cabrol
authors.forename: Bruno
authors.initials: B
authors.lastname: Carbonne
mesh_terms: D000318:Adrenergic beta-Agonists / Q000493:pharmacokinetics; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000493:pharmacokinetics; D009215:Myometrium / Q000378:metabolism*; D009529:Nicardipine / Q000493:pharmacokinetics; D009543:Nifedipine / Q000493:pharmacokinetics; D010120:Oxytocics / Q000493:pharmacokinetics; D011247:Pregnancy; D015149:Tocolytic Agents / Q000493:pharmacokinetics*
chemical_list: D000318:Adrenergic beta-Agonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010120:Oxytocics; D015149:Tocolytic Agents; D008278:Magnesium Sulfate; D009529:Nicardipine; D009543:Nifedipine